Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Miller

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Bone|October 26, 2018
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trialP D Miller, G Hattersley, E Lau, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 29, 2019
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonatesP D Miller, N Pannacciulli, J Malouf-Sierra, et al.
The American Journal of Medicine|December 1, 1993
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapyS T Harris, N B Watts, R D Jackson, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 14, 2010
"Evidence-based" or "logic-based" medicine?R D Blank, J P Bilezikian, S L Bonnick, et al.
Clinical Therapeutics|February 24, 2001
Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptomsP D Miller, G Woodson, A A Licata, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 11, 2012
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialM R McClung, E M Lewiecki, M L Geller, et al.
JAMA|December 12, 2001
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk AssessmentE S Siris, P D Miller, E Barrett-Connor, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 17, 2016
Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 studyR Rizzoli, C-L Benhamou, J Halse, et al.
The New England Journal of Medicine|February 15, 2001
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupM R McClung, P Geusens, P D Miller, et al.
The New England Journal of Medicine|July 12, 1990
Intermittent cyclical etidronate treatment of postmenopausal osteoporosisN B Watts, S T Harris, H K Genant, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Bone|October 26, 2018
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trialP D Miller, G Hattersley, E Lau, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 29, 2019
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonatesP D Miller, N Pannacciulli, J Malouf-Sierra, et al.
The American Journal of Medicine|December 1, 1993
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapyS T Harris, N B Watts, R D Jackson, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 14, 2010
"Evidence-based" or "logic-based" medicine?R D Blank, J P Bilezikian, S L Bonnick, et al.
Clinical Therapeutics|February 24, 2001
Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptomsP D Miller, G Woodson, A A Licata, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 11, 2012
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialM R McClung, E M Lewiecki, M L Geller, et al.
JAMA|December 12, 2001
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk AssessmentE S Siris, P D Miller, E Barrett-Connor, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 17, 2016
Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 studyR Rizzoli, C-L Benhamou, J Halse, et al.
The New England Journal of Medicine|February 15, 2001
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupM R McClung, P Geusens, P D Miller, et al.
The New England Journal of Medicine|July 12, 1990
Intermittent cyclical etidronate treatment of postmenopausal osteoporosisN B Watts, S T Harris, H K Genant, et al.
Pageof 18